02.04.2024 - BOSTON, April 02, 2024 (GLOBE NEWSWIRE) - Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders .
Jefferies Financial Group Raises Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $128.00 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Praxis Precision Medicines, Inc. Announces Proposed Public Offering tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.